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Outcome measure Emerging evidence 
Lipid profile Substantial amelioration of the atherogenic lipid profile in all studies
Insulin resistance Markedly improved insulin sensitivity in all studies 
Obesity No evidence of adipogenesis
Beneficial effects on bodyweight and a trend for reduced food intake observed in the majority of studies
Core emerging evidence summary for K-111 in the metabolic syndrome
Abstract
Introduction: Prevalence of the metabolic syndrome has increased dramatically in recent years. Optimal patient care demands a
multifaceted approach, with many individuals requiring several therapies to minimize the significant associated cardiovascular burden.
The need for novel agents in the management of the metabolic syndrome is emphasized by the current lack of drugs to treat insulin
resistance, one of the major components of the metabolic syndrome that has several deleterious consequences.
Aims: The objective of this review is to assess the emerging evidence for the potential use of K-111 in treatment of the metabolic
syndrome.
Emerging evidence: K-111 is a peroxisome proliferator-activated receptor (PPAR)-alfa agonist that, in preclinical studies, has shown
efficacy in improving insulin resistance, reducing bodyweight, and ameliorating atherogenic dyslipidemia. Preliminary evidence suggests
that toxicity and adverse events are low.
Profile: The improvements in obesity and insulin resistance, together with other beneficial effects following activation of PPAR alfa by
K-111 in preclinical models, are encouraging and offer several potential advantages over currently available therapies for patients with
the metabolic syndrome. However, K-111 is at an early stage of development and establishment of its role will require full analysis of
clinical trials carefully designed to determine its overall benefits in this increasingly important disease area.
Key words: BM 17.0744, cardiovascular diseases, insulin resistance, K-111, metabolic syndrome X, PPAR alfa
 Scope, aims, and objectives
K-111 (F. Hoffmann-La Roche), formerly known as BM 17.0744
[2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid], is a
peroxisome proliferator-activated receptor (PPAR)-alfa agonist.
K-111 is an insulin sensitizer and is currently undergoing phase II
clinical trials. Low insulin sensitivity (insulin resistance) is a major
component of the metabolic syndrome. This review provides an
overview of the metabolic syndrome and examines the emerging
evidence of a role for K-111 in the treatment of this condition.
Methods
The English language literature was searched in July 2005 in the
following databases. The search terms were “K-111,” “K111,”
and “BM 17.0744,” with minor variations in syntax applied to
some databases to resolve inappropriate data retrieval. No date
cut-offs were used except where stated.
• PubMed, http://www.ncbi.nlm.nih.gov/entrez
• EMBASE, http://www.datastarweb.com
• BIOSIS Previews, http://www.datastarweb.com
• York University Centre for Reviews and Dissemination
databases: Database of Abstracts of Reviews of Effects
(DARE); Health Technology Assessment (HTA); National Health
Service Economic Evaluation Database (NHSEED),
http://www.york.ac.uk/inst/crd/crddatabases.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://cochrane.org/index0.htm
• Clinical Evidence (BMJ), http://clinicalevidence.com
• National Guideline Clearing House, http://www.guideline.gov
• Clinical trial registers, http://www.clinicaltrials.gov,
http://clinicalstudyresults.com, http://controlled-trials.com 
A total of 40 articles were retrieved (38 full papers and two abstracts).
Searching of abstracts presented at congresses of the following
societies did not identify any additional abstracts: International
Diabetes Federation (IDF) and European Association for the Study of
Diabetes (2002–2004); American Diabetes Association (2003–2005);
American Heart Association (2004); European Atherosclerosis
Society (2004, 2005); European Society for Cardiology (2003).
A total of 29 papers were excluded because they did not
specifically concern K-111, or had no direct relevance to the
metabolic syndrome, or were general review papers, leaving nine
papers and two abstracts for evaluation (Table 1). There was no
clinical evidence available and all 11 publications included in the
evidence base were outcomes from preclinical studies. 
Disease overview
The metabolic syndrome is defined by the disproportionate
clustering of several risk factors for cardiovascular disease (CVD)
within individuals, leading to a significant increase in associated
morbidity and mortality. Also referred to as syndrome X, the
deadly quartet, or dysmetabolic syndrome X, the metabolic
syndrome has a complex pathophysiology. Major components
recognized are atherogenic dyslipidemia, hypertension, central
obesity, insulin resistance with or without glucose intolerance or
diabetes, and proinflammatory and prothrombotic states (Reaven
1988; Sakkinen et al. 1999; Grundy et al. 2004a; Eckel et al. 2005).
Several sets of clinical criteria have been put forward for defining
the metabolic syndrome (WHO 1999; NCEP ATP III 2001; Balkau
et al. 2002; Einhorn et al. 2003; Grundy et al. 2004a; IDF 2005a).
Although there is general agreement as to the most important
components of the syndrome, each definition varies in the precise
thresholds and specific factors that are to be met in making a
positive diagnosis. The most frequently used criteria have been
those from the World Health Organization (WHO) and National
Cholesterol Education Program Adult Treatment Panel III (NCEP
ATP III) (Table 2), with the latter considered the more easily
implemented for routine clinical use. However, the IDF consensus,
which is the most recent definition (IDF 2005a), considers central
obesity to be a necessary requirement (Table 2) whereas this
factor is not mandatory for either the NCEP ATP III or WHO
recommendations.
Both prospective and retrospective studies have indicated that
the risks of cardiovascular morbidity and mortality are increased
in patients with the metabolic syndrome versus those without the
syndrome (Isomaa et al. 2001; Lakka et al. 2002a; Cohen et al.
2003; L’Italien et al. 2003; Girman et al. 2004; Hu et al. 2004; Malik
et al. 2004; Ninomiya et al. 2004). In the prospective Kuopio Heart
Study of middle-aged men, the risks of death from coronary heart
disease, CVD or total mortality in those with the WHO-defined
metabolic syndrome were increased by 2.9–3.3, 2.6–3.0, and
1.9–2.1, respectively (Lakka et al. 2002a). Subanalyses of patients
included in the landmark statin trials have similarly identified
increased risks of total and cardiovascular mortality (L’Italien et al.
2003; Girman et al. 2004).
Disease pathophysiology
Although there is general agreement as to the main components
of the metabolic syndrome, the complex interactions between
these factors are not well understood. Indeed, a recent statement
by the American Diabetes Association and the European
Association for the Study of Diabetes, while not disputing the
clustering of CVD risk factors within individuals, has questioned
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Category Number of records
Full papers Abstracts
Initial search 38 2
records excluded 29 0
records included 9 2
Table 1 | Evidence base included in the review
 171
whether there is sufficient evidence to warrant the designation of
“syndrome” (Kahn et al. 2005). However, it is thought that the two
most critical components are obesity and insulin resistance.
Obesity
Obesity is a major underlying cause of the metabolic syndrome,
affecting many of its individual components, including blood
pressure, cholesterol, triglycerides (TG), and insulin resistance.
Obesity is defined on the basis of body mass index (BMI);
however, definitions of the metabolic syndrome use measures of
central obesity rather than BMI on the basis that central obesity
(in particular visceral fat accumulation) is a more accurate
measure of cardiovascular risk than overall excess bodyweight
(Prineas et al. 1993; Rimm et al. 1995; Lakka et al. 2002b).
Abdominal obesity increases the risk of type 2 diabetes,
atherogenic dyslipidemia, and hypertension (Després et al. 2001). 
Insulin resistance
The initial description of the metabolic syndrome as centered on
insulin resistance emphasizes the important contribution of this
component. Insulin resistance is recognized as a precursor for
diabetes, which is well established as conferring higher CVD risk.
Approximately 65% of patients with diabetes die from heart
disease or stroke (CDC 2005). Overabundance of circulating free
fatty acids as a result of increased fat mass, particularly in deep
subcutaneous and visceral adipose depots, and large adipocytes
that are resistant to the ability of insulin to suppress lipolysis,
contribute to the development of insulin resistance and
compensatory hyperinsulinemia. Free fatty acids inhibit glucose
metabolism in skeletal muscle and stimulate gluconeogenesis in
the liver. Levels of adiponectin are decreased, reducing its insulin-
sensitizing effect. Although there is a correlation between insulin
resistance and increasing body fat, the relationship is complex; not
all obese patients are insulin resistant, and a broad range of insulin
sensitivities are observed at any given level of body fat (Abbasi et
al. 2002). Insulin resistance leads to a wide range of deleterious
metabolic changes, including the development of glucose
intolerance, overt diabetes, hypertriglyceridemia, and hypertension.
Dyslipidemia
The pattern of atherogenic dyslipidemia in patients with the
metabolic syndrome is similar to that in patients with diabetes and
is a result of insulin resistance, with a number of mediators involved
(e.g. hepatic lipase, lipoprotein lipase, cholesterol ester transfer
protein) (Ayyobi & Brunzell 2003). The effect of increasing free fatty
acid flux to the liver leads to increased production of apolipoprotein
B-containing, TG-rich, very-low-density lipoproteins (VLDL). TG
levels are increased and there is a reduction in high-density
lipoprotein cholesterol (HDL-C), accompanied by other
abnormalities including increased remnant lipoproteins, elevated
apolipoprotein B, small dense LDL particles, and small dense HDL
particles. All these lipid disturbances are established as
independent risk factors for CVD. Although raised LDL-C levels are
not a diagnostic feature of the metabolic syndrome, many patients
also have this additional CVD risk factor.
Hypertension
Hypertension has many causes that are unrelated to the
metabolic syndrome. Nevertheless, elevated blood pressure is
common in obese individuals and also occurs frequently in
association with insulin resistance. Numerous outcomes trials
have established hypertension as a major risk factor for CVD.
Proinflammatory state
The production by adipose tissue of proinflammatory cytokines,
such as tumor necrosis factor and interleukin (IL)-6, is increased
in patients with the metabolic syndrome (Grundy et al. 2004b) and
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WHO 1999 NCEP ATP III 2001 IDF 2005a
Requirement: Impaired glucose regulation or diabetes
and/or insulin resistance plus ≥2 of the
following:
≥3 of the following: ≥3 of the following, one of which must be
central obesity:
Central obesity  BMI >30 kg/m2 and/or waist-to-hip ratio:
men >0.90; women >0.85
Waist circumference: men >102 cm;
women >88 cm
Waist circumference: men ≥94 cm;
women ≥80 cm
Fasting glucose ≥6.1 mmol/L (110 mg/dL) ≥5.6 mmol/L (100 mg/dL)
Triglycerides ≥1.7 mmol/L (150 mg/dL)a ≥1.7 mmol/L (150 mg/dL) ≥1.7 mmol/L (150 mg/dL)a
HDL-C Men: <0.9 mmol/L (35 mg/dL)
Women: <1.0 mmol/L (39 mg/dL)
Men: <1.0 mmol/L (40 mg/dL)
Women: <1.3 mmol/L (50 mg/dL)
Men: <1.03 mmol/L (40 mg/dL)
Women: <1.29 mmol/L (50 mg/dL)
Microalbuminuria Urinary albumin excretion rate ≥20 µg/min
or albumin : creatinine ratio ≥30 mg/g
Blood pressure ≥140/90 mmHg ≥130/85 mmHg ≥130/85 mmHga
aIncluding treatment for this condition.
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; NCEP ATP, National Cholesterol Education Program Adult Treatment Panel; WHO,
World Health Organization.
Table 2 | Criteria for definition of the metabolic syndrome
 may lead to inappropriate inflammatory cascades and
subsequent tissue destruction. In contrast, levels of adiponectin,
which enhances insulin sensitivity and has an inhibitory effect at
several stages of the inflammatory process (Lee & Pratley 2005),
are decreased (Matsuzawa et al. 2004). In addition, levels of C-
reactive protein (CRP), a marker of inflammation that is a strong
independent indicator of incident CVD, are often elevated in
patients with the metabolic syndrome (Fröhlich et al. 2000; Mora
et al. 2003; Ridker et al. 2003), with a marked correlation between
CRP levels and the number of metabolic syndrome components
present (Fröhlich et al. 2000; Ridker et al. 2003).
Prothrombotic state
An unfavorable balance between prothrombotic and fibrinolytic
factors, leading to a hypercoagulable state, is another feature of
the metabolic syndrome (Nieuwdorp et al. 2005). Increased levels
of clotting factors and inhibition of the fibrinolytic pathway are
accompanied by greater platelet aggregability, all of which
increase the risk of thrombotic events. Plasma levels of
plasminogen activator inhibitor (PAI)-1 (a marker of decreased
fibrinolytic capacity) and fibrinogen may be raised. Depressed
plasmin levels may enhance the progression of atherosclerosis in
individuals with hyperinsulinemia or glucose intolerance
(Sakkinen et al. 1999).
Epidemiologic profile
Both genetic and environmental factors determine the prevalence
of the metabolic syndrome and its individual components. In
addition, estimates of the prevalence of the metabolic syndrome
vary with the different criteria used for its definition and with the
population demographics of individual studies. Comparison of the
NCEP ATP III and WHO criteria in the National Health and Nutrition
Examination Survey (NHANES) III in the United States provided
age-adjusted prevalences of 23.9 and 25.1%, respectively, with
concordance in 86.2% of subjects although there were marked
differences in certain ethnic groups (Ford et al. 2003). In contrast,
applying the WHO and IDF criteria to a Greek population revealed
markedly different values of 24.5 and 43.4%, respectively, causing
the authors to question the validity of the less demanding IDF
definition (Athyros et al. 2005). However, there is general
agreement that the overall prevalence is projected to increase
dramatically in the future. This is attributable to several factors. 
Firstly, the metabolic syndrome is more common in older
individuals, and greater longevity means that the elderly
contribute to an increasingly large proportion of populations. In
the NHANES survey in the USA, prevalences ranged from 6.7% in
those aged 20–29 years, to 43.5% in the ≥60 years age group
(Ford et al. 2002). Second, the two components that many would
agree are central to development of the metabolic syndrome,
obesity and insulin resistance, are on the increase.
Obesity has become a global problem and is no longer restricted
to developed countries. Recent data indicate that more than a
billion adults are classified as overweight (BMI ≥25 kg/m2), and the
number of obese (BMI ≥30 kg/m2) people is >300 million (WHO
2003; James et al. 2004), reflecting at least a doubling in the
prevalence of obesity over less than two decades. Furthermore,
there has been an accompanying increase in childhood obesity
(James et al. 2004). Higher BMIs are correlated with a greater
prevalence of the metabolic syndrome (Park et al. 2003).
The number of individuals with diabetes (171 million in 2000) is
projected to increase to 366 million by 2030, equivalent to a
global prevalence of 4.4% (Wild et al. 2004). The burden of
diabetes is well established, and many patients die from
cardiovascular complications. Type 2 diabetes, which has
previously been considered a disease of adulthood, is now
occurring in children in parallel with sedentary lifestyles and
increasing obesity (Drake et al. 2002; Kaufman 2002). It is not
surprising, therefore, that the metabolic syndrome is also being
detected at an increasing frequency in children and adolescents
(Falkner et al. 2002; de Ferranti et al. 2004; Duncan et al. 2004;
Weiss et al. 2004).
Burden of disease
There is no doubt that the metabolic syndrome impacts significantly
on economic and healthcare resources. Raised BMI, high
cholesterol and high blood pressure are among the top five leading
risk factors for the burden of disease in developed countries (WHO
2002b). Obesity is killing about 220 000 men and women every year
in the USA and Canada alone, and about 320 000 men and women
in 20 countries of Western Europe (WHO 2002b). Crude estimates of
the costs of obesity and its comorbidities amount to 7% of total
healthcare budgets in some countries (James et al. 2004). Death due
to diabetes is mainly due to cardiovascular complications and many
are premature, when the people concerned are making an economic
contribution to society. Direct healthcare costs range from 2.5 to
15% of annual healthcare budgets, depending on prevalence and
sophistication of treatment. The estimated cost of treating diabetes
in the USA in 1997 was $US44 billion (WHO 2002a).
A considerable proportion of coronary heart disease morbidity
and mortality is not accounted for by traditional risk-prediction
formulae. This may explain why an increased risk of CVD is
associated with the metabolic syndrome even after traditional risk
factors are accounted for (Lakka et al. 2002a). However, it is
debatable whether adding the risk factors for metabolic syndrome
may be of use in improving the accuracy of CVD risk using other
methods, such as the Framingham algorithm (Wilson et al. 1998;
Girman et al. 2004; Stern et al. 2004). Furthermore, the merit of
adding CRP as a clinical criterion for the metabolic syndrome
and/or the development of a CRP-modified coronary risk score is
an important area for debate (Ridker et al. 2004). Recently, it has
been noted that some of the cut-off points used to define the
metabolic syndrome are set arbitrarily, and categorizing patients
as candidates for treatment on this basis is not necessarily
appropriate (Kahn et al. 2005). Consistent with this, the vascular
event risk for patients with the IDF-defined metabolic syndrome
using the Framingham risk engine has been estimated as 6.1%,
significantly lower (P<0.0001) compared with an estimate of
11.3% for patients with the NCEP ATP III-defined metabolic
syndrome (Athyros et al. 2005). However, all chronic progressive
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diseases are marked by cut-off points and it is not uncommon for
these to vary within a single condition. Some guidelines
recommend conservative cut-off points whereas others advocate
more stringent levels for diagnosis on the basis that earlier
treatment is potentially better. Variations in disease definitions
also reflect the interests and concerns of different professional
bodies; for the metabolic syndrome this includes diabetologists,
cardiologists, and epidemiologists.
Current therapy options
There are currently no evidence-based guidelines solely aimed at
treating patients with the metabolic syndrome. However, the
American Heart Association, the National Heart, Lung, and Blood
Institute, and the American Diabetes Association have issued a
joint scientific statement on the management of the metabolic
syndrome (Grundy et al. 2004b). Advice on treating the syndrome
or its components are included in obesity, hypertension, diabetes,
and CVD guidelines (National Heart, Lung, and Blood Institute
1998; WHO 1999; NCEP ATP III 2001; De Backer et al. 2003; ADA
2004; Klein et al. 2004; IDF 2005b). In addition, the IDF have
included treatment advice in their recent consensus definition of
the metabolic syndrome (IDF 2005a).
Management of the metabolic syndrome is aimed at minimizing
the risk of developing CVD or overt diabetes. However, the risk is
not uniform for all patients and it is recommended that 10-year
CVD risk assessments (NCEP ATP III 2001; Conroy et al. 2003) are
carried out for all patients to determine their optimal treatment
strategy (Eckel et al. 2005). Whether the inclusion of less
traditional risk factors (e.g. insulin resistance, apolipoprotein B
levels) will improve CVD risk assessment has not been clarified. 
Advice is consistent in advocating lifestyle changes (e.g. reducing
obesity, increasing physical activity, and reducing saturated fat
intake) as the first-line treatment option for the metabolic
syndrome since these simultaneously improve many symptoms
(e.g. lowering of blood pressure, improvements in insulin
resistance, and a less-atherogenic lipid profile). However,
pharmacologic intervention is frequently required to enable
patients to achieve advocated target levels for individual risk
factors. The current approach is to address each risk factor as a
separate entity and prescribe several pharmacologic therapies in
parallel; nevertheless, it is becoming apparent that the pleiotropic
characteristics of certain agents provide additional benefits
beyond their principal therapeutic action. Recognition of the
potential benefits of single agents to induce multiple risk
reduction reinforces the concept that the individual symptoms of
the metabolic syndrome are the end result of a complex series of
interactions and should not be considered in isolation.
Antihypertensive agents
Although guidelines for the management of hypertension vary in
the exact blood pressure levels at which pharmacologic
intervention is recommended, they are unanimous in recognizing
the need for more stringent targets in individuals with
comorbidities such as diabetes and preexisting CVD (Chobanian
et al. 2003; ESH/ESC 2003; Whitworth 2003; Williams et al. 2004).
No agents in particular are specified for treating patients with the
metabolic syndrome but many patients will require combination
therapy to attain blood pressure goals.
Lipid-modifying agents with pleiotropic effects
Statins
It is well established that statins are the most effective agents for
lowering LDL-C levels; they also raise HDL-C levels, lower TG,
and reduce the number of apolipoprotein B-containing
lipoproteins. Patients with features of the metabolic syndrome
have been included in some of the major outcomes trials of
statins that have shown these agents to be of significant benefit
in reducing cardiovascular morbidity and mortality. Subgroup
analyses of these and of studies where changes in lipid levels
were the primary endpoint have indicated that the benefits extend
to patients with the metabolic syndrome (Ballantyne et al. 2001;
Hunninghake et al. 2003; Sattar et al. 2003). In addition to their
beneficial effects on the lipid profile, other pleiotropic effects of
statins have been identified, including improving endothelial
dysfunction, reducing inflammation, and antithrombotic
properties (Bellosta et al. 2000; Liao 2002; Sowers 2003).
PPAR-alfa agonists
Fibric acid derivatives (fibrates) are PPAR-alfa agonists and have
been shown to beneficially affect the atherogenic profile. They are
especially effective at raising HDL-C levels and lowering TG and
their ability to reduce cardiovascular morbidity and mortality has
been established in outcomes trials such as the Veterans Affairs
HDL Intervention Trial (VA-HIT; Rubins et al. 1999) and the Helsinki
Heart trial (Frick et al. 1987). As with the statins, evidence for the
beneficial effects of fibrates on cardiovascular outcomes in
patients with the metabolic syndrome is limited to retrospective
subanalyses. In the VA-HIT trial, the greater reduction in
cardiovascular events with gemfibrozil in subjects with insulin
resistance than in those without, despite the smaller
improvements in HDL-C and TG in the former group, supports the
broader benefits of PPAR-alfa agonists that are lipid-independent
(Robins et al. 2003). Similarly, in the Helsinki Heart Study,
gemfibrozil reduced coronary risk mainly in overweight subjects
with additional risk factors related to insulin resistance (Tenkanen
et al. 1995). The most dyslipidemic group (TG >2.3 mmol/L and
LDL-C/HDL-C ratio >5) benefited most from gemibrozil treatment
(Manninen et al. 1992). In the Bezafibrate Infarction Prevention
Study, bezafibrate reduced the incidence of myocardial infarction
in patients with the metabolic syndrome, with a marked
strengthening of cardiac mortality reduction in patients with
4–5 metabolic syndrome risk factors (Tenenbaum et al. 2005).
PPAR-alfa agonists may also have important nonlipid actions
including antiinflammatory, insulin-sensitizing, and vasoprotective
actions (Berger et al. 2005; Tsimihodimos et al. 2005). For
example, after 3 months of fenofibrate therapy, insulin resistance
was reduced in patients with dyslipidemia and the metabolic
syndrome (Wysocki et al. 2004).
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Niacin has beneficial effects on several aspects of atherogenic
dyslipidemia and the HDL Atherosclerosis Treatment Study
(HATS) showed that in combination with simvastatin, it augments
the regression of proximal coronary stenosis and reduces the
frequency of cardiovascular events in patients with low HDL-C
levels and many other features of the metabolic syndrome (Brown
et al. 2001). Inhibitors of cholesterol ester transfer protein (e.g.
torcetrapib) currently in development may also be useful either
alone or in combination with statins in patients with low HDL-C
(Brousseau et al. 2004).
Treating insulin resistance and type 2 diabetes
Weight reduction and increased physical activity are the initial
strategy for reducing insulin resistance. Treatment with
biguanides and thiazolidinediones reduces insulin resistance and
prevents or delays the onset of type 2 diabetes in patients with
prediabetes (elevated fasting and/or postload glucose levels)
(Buchanan et al. 2002; Knowler et al. 2002; Durbin 2004).
Metformin is well established as a treatment for type 2 diabetes
(UKPDS 34 1998). In the Diabetes Prevention Program, both
lifestyle intervention and metformin therapy reduced the
development of the metabolic syndrome (Orchard et al. 2005).
The more recently introduced thiazolidinediones are insulin
sensitizers that stimulate PPAR gamma, leading to insulin-
responsive proteins (Yki-Järvinen 2004). A study comparing the
effect of pioglitazone, metformin, and a sulfonylurea on the
metabolic syndrome and its components in patients with poorly
controlled type 2 diabetes showed that although all agents
significantly decreased the proportion of patients with the
metabolic syndrome, pioglitazone, in addition to improving blood
glucose control, had the greatest beneficial effects on blood
pressure and TG and HDL-C levels (Rajagopalan et al. 2005).
Clearly, patients who have already developed diabetes should be
treated in accordance with diabetes-specific recommendations
(ADA 2004; IDF 2005b). For example, it is well established that
good glycemic control is beneficial in preventing complications of
diabetes (UKPDS 33 1998). 
Prothrombotic and proinflammatory states
Low-dose aspirin is recommended for all patients with CVD.
However, there is no evidence base for its role in primary
prevention of CVD, even in those with type 2 diabetes. Statins
have the potential to ameliorate the prothrombotic state by
mechanisms that include reducing platelet aggregation and
promoting fibrinolytic activity through the reduction of PAI-1 levels
(Rosenson & Tangney 1998; Liao 2002; Sowers 2003).
Strategies to reduce the underlying causes of inflammation in
patients with the metabolic syndrome are limited to the pleiotropic
effects of statins and fibrates (see above). In addition,
thiazolidinediones have been reported to reduce levels of CRP
(Nesto 2004).
Unmet needs
The complex pathophysiology underlying the metabolic
syndrome requires the combination of different agents with
divergent modes of action, as discussed above. This necessitates
polypharmacy for most patients, with the potential for unwanted
drug–drug interactions and associated adverse events (e.g.
rhabdomyolysis following some statin-fibrate combinations) as
well as poor adherence to medication due to complicated
regimens. The introduction of drugs with modes of action against
the “root causes” of the metabolic syndrome that lead to
concomitant improvements in multiple aspects of the metabolic
syndrome would clearly be of benefit to both patients and
physicians, as well as impacting favorably on the economic
burden. Although there is still room for improvement in
antihypertensive and lipid-modifying therapies, it is other aspects
of the metabolic syndrome such as insulin resistance and
inflammation where there is the greatest potential for better
treatment. The requirement for compounds that enhance insulin
sensitivity is only partially fulfilled by thiazolidinediones.
Thiazolidinediones have significant antidiabetic efficacy but their
use is associated with adverse events including hemodilution,
edema, adipogenesis, weight gain, toxic effects on the liver, and
carcinogenic potential (Yki-Järvinen 2004). The results of the first
outcomes study with thiazolidinediones, the PROspective
pioglitAzone Clinical Trial In macroVascular Events (PROactive),
were released in September 2005. In high-risk patients with type
2 diabetes, pioglitazone reduced the composite of all-cause
mortality, nonfatal myocardial infarction, and stroke (PROactive
Steering Committee 2005). However, no outcomes studies with
thiazolidinediones in patients with the metabolic syndrome are
available. Similarly, although a reduction in some cardiovascular
endpoints were observed with metformin in obese patients with
diabetes (UKPDS 34 1998), to date there are no CVD endpoint
trials with metformin in patients with the metabolic syndrome.
There are also dose-limiting toxic effects of metformin.
The pleiotropic effects of statins and fibrates that lead to
improvements on nonlipid variables are not well clarified. Fibrates
are relatively nonspecific ligands of PPAR alfa and have weak
affinity, requiring high doses for efficacy. PPAR alfa plays a role in
the inflammatory response at the vascular, splenic, and hepatic
levels. Its antiinflammatory actions include inhibiting IL-1-induced
IL-6 secretion, decreasing the expression of adhesion molecules
on endothelial cells, and repressing the expression of certain
acute-phase proteins in the liver (reviewed by Delerive et al.
2001). These observations are consistent with the amelioration of
inflammation seen following administration of fibrates to patients
with atherosclerosis or with hyperlipoproteinemia (Madej et al.
1998; Staels et al. 1998).
Drug review
With increasing knowledge of PPAR-alfa structure and function,
specifically designed PPAR-alfa activators that have the potential
for increased efficacy, potency and selectivity, and decreased
adverse events are being developed, with several structurally
distinct compounds under consideration (Miyachi 2004). K-111 is
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one such compound. Phase II trials of K-111 are currently
underway in Europe, the USA, and Japan, but no information is
available regarding the trial design, the type of patients included,
or the endpoints of the study, nor are there any published clinical
data. As discussed below, properties of K-111 that have been
assessed in preclinical studies include its effects on the lipid
profile, cardiac metabolism, bodyweight, and hyperinsulinemia.
For K-111 to prove a viable addition to currently available
treatments for the metabolic syndrome, clinical studies need to
demonstrate beneficial effects on all of these variables that are at
least equal to those of other agents aimed at individual disease
components and preferably with a lower rate of adverse events.
Furthermore, determining the impact of K-111 on less-well-
defined aspects of the metabolic syndrome such as inflammation
(e.g. by measuring CRP levels) will provide information that
distinguishes it from other agents.
Preclinical evidence 
K-111 has been evaluated in mice, rats, guinea pigs, dogs, and
nonhuman primates. Studies have included various rodent
models of diabetes, rhesus monkeys with a metabolic syndrome
phenotype with different genetic backgrounds, and healthy
animals.
Lipid profile
All studies have demonstrated an improvement in serum
hypertriglyceridemia with K-111 administration (Meyer et al. 1999;
Pill & Kühnle 1999; Pill & Meyer 1999; Bodkin et al. 2003a,b;
Schäfer et al. 2004; Ortmeyer et al. 2005). For example, sequential
administration of K-111 at doses of 1, 3, and 10 mg/kg per day
(4 weeks for each dose) to obese rhesus monkeys reduced TG by
30, 50, and 53%, respectively (Bodkin et al. 2003a). The levels of
other lipid variables that are often abnormal in patients with the
metabolic syndrome, such as large VLDL fractions and HDL-C
and its subfractions, were also improved with K-111 treatment in
obese rhesus monkeys but reductions in serum cholesterol were
restricted to rodents and dogs (Meyer et al. 1999; Bodkin et al.
2003a,b; Ortmeyer et al. 2005). 
There are also species differences in the effects of K-111 in
healthy animals. K-111 altered lipid levels in metabolically
normal rats to a similar extent to that seen with bezafibrate, with
nearly maximal lipid reductions obtained with the lowest dose of
K-111 administered (1.5 mg/kg per day) (Meyer et al. 1999).
In contrast, K-111 did not alter TG levels in healthy cynomolgus
monkeys, which is consistent with the regulatory effect of
PPAR alfa on lipid metabolism (Schäfer et al. 2004). The
elevation of beta-oxidation enzymes, leading to enhancement of
fatty acid catabolism, is likely to partially explain the lipid-
altering potency of K-111 (Meyer et al. 1999; Schäfer et al.
2004). As previously observed for fibrates, the excessive
enhancement of beta-oxidation enzymes by K-111 in rats that
leads to liver weight increase is not evident in primates, where
modest increases in beta oxidation of up to three-fold similar to
that seen in guinea-pigs and dogs were detected (Meyer et al.
1999; Schäfer et al. 2004).
Cardiac metabolism and function
PPAR alfa is highly expressed in the heart but very little is known
as to how PPAR ligands affect cardiac function. In-vitro
experiments on rat cardiomyocytes have indicated that K-111
inhibits the cardiac activity of the PPAR target lipoprotein lipase by
a posttranscriptional and posttranslational mechanism, reducing
the availability of fatty acid products for tissue utilization (Carroll &
Severson 2001). In support of these data, K-111 leads to
normalization of the altered cardiac metabolism (reduced glucose
use, elevated fatty acid oxidation, and higher endogenous
triacylglycerol content) characteristic of the db/db mouse model
by increasing the rates of cardiac glycolysis and myocardial
glucose oxidation in the db/db mouse models of diabetes by 1.7-
and 2.3-fold, respectively (Aasum et al. 2002). However, these
changes are not observed in control animals, suggesting that the
metabolic alterations reflect indirect mechanisms related to an
improvement in diabetic status (Aasum et al. 2005). In addition,
K-111 did not have any effect on mechanical cardiac function in
the db/db model (Aasum et al. 2002, 2005).
Bodyweight
A dose-dependent decrease in bodyweight has been observed in
all studies of obese rhesus monkeys (Bodkin et al. 2003a, Schäfer
et al. 2004; Ortmeyer et al. 2005). In a dose-escalation study,
compared with vehicle treatment there was significant weight loss
of 2, 4, and 8% with K-111 (1, 3, and 10 mg/kg day) (P<0.001),
accompanied by decreases in food intake of 10, 17, and 31%,
respectively (Bodkin et al. 2003a). These data are in contrast to
the effect of fenofibrate in obese rhesus monkeys, in which
bodyweight and food intake were not altered (Winegar et al.
2001). Significant weight reduction was also observed in healthy
cynomolgus monkeys treated with K-111 20 mg/kg per day for
13 weeks (13% in males, 7% in females; P value not provided in
the paper) compared with vehicle control, with less pronounced
effects at lower doses (Schäfer et al. 2004). In rodents, there was
no increase (and in some studies a decrease) in bodyweight
associated with K-111 (Pill & Kühnle 1999; Aasum et al. 2002,
2005). In a comparative study of the effect of 4 weeks’ treatment
with K-111 (1.5 to 12.5 mg/kg per day) or bezafibrate (25 or 75
mg/kg per day) in healthy rats, bodyweight gain was significantly
lower in the K-111 12.5 mg/kg per day group and there was a
tendency for lower values at 3 and 6 mg/kg per day, compared
with controls, whereas values for both bezafibrate groups were
similar to those in the control group (Pill & Kühnle 1999). 
Insulin resistance
In rodent models of type 2 diabetes with different genetic
backgrounds (ob/ob, db/db and yellow KK mice, obese fa/fa
Zucker rats) that confer a range of abnormalities of insulin
metabolism, hyperglycemia and hyperinsulinemia were improved
markedly with administration of K-111 (Pill & Kühnle 1999). These
data are consistent with initial in-vitro studies. In a comparative
study of K-111 and troglitazone in yellow KK mice, improvements
in glucose and insulin levels were greater with K-111 and achieved
at lower doses than with troglitazone (Pill & Meyer 1999). In studies
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doses and time periods significantly improved hyperinsulinemia
and increased glucose uptake, confirming the beneficial effects on
insulin sensitivity observed in rodents (Bodkin et al. 2003a,b;
Schäfer et al. 2004). However, K-111 does not alter blood glucose
in normoglycemic rodents or primates, indicating that
hypoglycemia is unlikely to be a problem should K-111 be
administered to patients with the metabolic syndrome in the
absence of hyperglycemia (Pill & Kühnle 1999; Schäfer et al. 2004).
The mechanism of action of K-111 in improving whole body
insulin sensitivity has been examined in obese rhesus monkeys
(Bodkin et al. 2003b; Ortmeyer et al. 2003, 2005). K-111
significantly reduces skeletal muscle TG content in obese rhesus
monkeys and it is suggested that this reduction, secondary to an
increase in fatty acid oxidation, leads to an increase in total
glycogen synthase activity and subsequent improved insulin
sensitivity (Ortmeyer et al. 2003, 2005). Glucose tolerance and
beta-cell acute insulin response are not significantly affected by
K-111 administration (Bodkin et al. 2003b). Rather, K-111’s
contribution to improving the metabolic syndrome includes
mitigating insulin resistance.
Pharmacokinetics and toxicity
The study by Meyer et al. (1999) included a pharmacokinetic
study of K-111 (day 22 of a 28-day administration period) in dogs
and rats. In rats, K-111 has a half-life of 2 hours whereas in dogs,
the long half-life (40 hours) leads to high systemic exposure even
at 1.5 mg/kg per day and a pretoxicity study indicated that doses
≥4 mg/kg per day should be regarded as toxic. Pharmacokinetic
parameters determined after a single administration of K-111 in
mice, rats, dogs, and monkeys are consistent with these data,
indicating a short half-life for mice, rats, and monkeys, even in the
case of high dosing whereas a long half-life was seen in dogs (Pill
& Meyer 1999).
K-111 was well tolerated in the pharmacologic dose range tested
in rodent species (Pill & Kühnle 1999). No adverse effects or signs
of toxicity have been reported in obese monkeys (Bodkin et al.
2003a; Schäfer et al. 2004). 
Resource utilization
Lifestyle interventions including diet and moderate physical
activity can reduce the risk of developing type 2 diabetes by as
much as 40–60% and at least half of all diabetes cases would be
eliminated if weight gain in adults could be prevented (IDF 2005a).
A reduction of 5–10% in bodyweight is sufficient to significantly
improve comorbidities associated with obesity. Although lifestyle
interventions do not incur drug costs, their successful
implementation and adoption require time and resource
allocation, including the development and application of
strategies designed to optimize patient cooperation and
continued participation in following diet and exercise programs.
An important aspect of managing the burden of the metabolic
syndrome is the accurate identification of patients so that
appropriate lifestyle and/or pharmacologic interventions can be
initiated. Physicians and other healthcare professionals who are
aware of the clustering of several risk factors within individuals are
in a good position to ensure that all identified risk factors are
quantified and treated to minimize subsequent cardiovascular risk
and the development of diabetes. Addressing elements of the
syndrome that have multiple deleterious consequences is clearly
of major importance.
A single agent that impacts simultaneously and significantly on
several aspects of the metabolic syndrome has the potential to
have both clinical and economic advantages. However, such an
agent must meet certain criteria for such a potential to be
fulfilled. Firstly, the metabolic syndrome is heterogeneous and
individual patients will vary in the combination and extent of
their symptoms. Patients who are likely to benefit most from
treatment with K-111 are those with multiple metabolic
abnormalities. However, to widen the eligibility for treatment
with K-111, it will need to be demonstrated that administering
K-111 to normalize some components of the syndrome (e.g.
reducing bodyweight, improving the lipid profile) does not
impact adversely on another parameter (e.g. unwanted
induction of hypoglycemia). Second, the selectivity of K-111 for
PPAR alfa means that its insulin-sensitizing and lipid
normalization properties have to be at least equivalent to those
associated with PPAR gamma or PPAR-alfa/gamma agonists
but with a superior side-effect profile. Third, any evidence that
K-111 has additional pleiotropic effects such as those
associated with diabetes medications and statins will be
important in understanding its mode of action and applicability
in the treatment of other conditions. 
The ultimate test of K-111’s economic benefit will be the
demonstration that it significantly reduces morbidity and mortality
associated with the metabolic syndrome to a greater extent
and/or at lower cost than the combination of agents currently
available for treating dyslipidemia and insulin resistance.
However, in the shorter term, its use will be justified if it can be
shown that using K-111 reduces the need for polypharmacy
without compromising efficacy.
Drug profile
Insulin resistance is more common in overweight individuals
(McLaughlin et al. 2003). Ameliorating the pathology associated
with insulin resistance by stimulating the PPAR-alfa pathway is an
attractive strategy because of beneficial effects on the lipid profile
and inflammation that occur in addition to improving glucose
homeostasis. Agents with high specificity for PPAR alfa, such as
K-111, have the potential to decrease the cardiovascular risk
associated with the metabolic syndrome in a superior manner to
the currently available fibrates. Although the data for K-111 are
limited to preclinical studies, the observation of marked
improvements in lipid profiles, hyperinsulinemia, and obesity in
nonhuman primates with features of the metabolic syndrome are
encouraging. In addition, the almost uniform pharmacologic
responses to K-111 observed in obese rhesus monkeys with
varied genetic background and pathophysiology is consistent
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with studies in rodents and suggest that the action of K-111 is
independent of the nature of the metabolic disturbance (Schäfer
et al. 2004).
In the longer term, it will be important to assess the relative merits
of K-111 versus PPAR-alfa/gamma dual agonists (glitazars) that
are currently under investigation for treating diabetes and the
metabolic syndrome. For example, approval of muraglitazar for
the treatment of type 2 diabetes was recommended by a Food
and Drug Administration advisory panel in September 2005.
However, in a marked number of patients, muraglitazar causes
fluid retention that has the potential to lead to congestive heart
failure (Buse et al. 2005).
The most robust endpoint for future studies of K-111 would
clearly be outcomes studies measuring cardiovascular events,
but these require several years of follow-up of a large population
of patients. However, studies using surrogate endpoints (e.g.
measuring lipid profiles) whose normalization has already been
shown to reduce cardiovascular morbidity and mortality will also
provide important information. Indeed, the complexity and
number of metabolic pathways that are dysregulated in the
metabolic syndrome and that could be affected by K-111
treatment (Fig. 1) make it desirable for a broad spectrum of
variables (e.g. relating to inflammation, vascular function,
hypertension, and lipids) to be included in addition to primary
endpoints.
Whatever definition of the metabolic syndrome is chosen for
future studies, there will always be a certain degree of
heterogeneity among study patients, with individual patients
varying in which and how many of the designated criteria for the
metabolic syndrome are met. In addition, it is not known whether
different combinations of metabolic syndrome components
confer the same cardiovascular risk. To minimize this, it would
seem appropriate to design trials such that the spread of relevant
baseline characteristics is kept to a minimum or at least controlled
for so that there is sufficient power in the study to allow
multivariate or predetermined subgroup analyses.
In summary, clinical trials of K-111 are awaited to determine
whether its preclinical potential is realized in patients with the
metabolic syndrome.
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